Safe withdrawal of immune meds after liver transplant
This study tests whether long-term liver transplant recipients (5+ years after transplant) can safely stop or reduce their immunosuppressant medications by checking for donor cells (chimerism) in the liver. If you have stable liver function and agree to a liver biopsy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a liver transplant (from a living or deceased donor) at least 5 years ago.
- Your liver function tests (blood tests) are stable and within normal limits.
- You are at least 20 years old and feeling well enough to do daily activities (fully active or able to do light work).
- You are willing to have a liver biopsy to check for donor cells in your liver.
- No active infections, recent cancers, or signs of rejection in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
This trial tests whether children who had a liver transplant before age 6 can safely stop taking their anti-rejection medicine. It's for children who are doing well — with normal liver function and no signs of rejection or scarring — at least 4 years after transplant.
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.